|
|
转录因子MYBL2在恶性肿瘤中的研究进展
|
Abstract:
成髓细胞瘤转录因子第2亚型(MYB proto-oncogene like 2, MYBL2)是MYB转录因子家族的成员，参与多种细胞的增殖、分化、凋亡。近年来，MYBL2作为一种转录调节因子，被发现其在肿瘤、炎性疾病等疾病中具有重要作用。一方面，MYBL2直接与启动子结合区域结合，另一种通过与其他蛋白质相互作用结合。随着研究的深入，MYBL2在恶性肿瘤中的调控作用及分子机制逐步被揭示，但在不同肿瘤中的调控效应不尽相同。现在还需进一步研究MYBL2在各种恶性肿瘤中的调节机制，在未来MYBL2有成为恶性肿瘤的治疗靶点可能。本文根据近年恶性肿瘤中MYBL2的作用及其分子机制展开综述，为今后的研究提供新思路。
MYB proto-oncogene like 2 (MYBL2) is a member of the MYB transcription factor family and is involved in the proliferation, differentiation and apoptosis of various cells. In recent years, MYBL2, as a transcriptional regulator, has been found to play an important role in tumors, inflammatory diseases and other diseases. On one hand, MYBL2 binds directly to promoter binding regions, and the other binds by interacting with other proteins. With the deepening of research, the regulatory role and molecular mechanism of MYBL2 in malignant tumors have been gradually revealed, but the regulatory effect in different tumors is not the same. It is still necessary to further study the regulatory mechanism of MYBL2 in various malignant tumors, and MYBL2 may become a therapeutic target for malignant tumors in the future. In this paper, we reviewed the role and molecular mechanism of MYBL2 in malignant tumors in recent years, providing new ideas for future research.
| [1] | Musa, J., Aynaud, M., Mirabeau, O., Delattre, O. and Grünewald, T.G. (2017) MYBL2 (B-Myb): A Central Regulator of Cell Proliferation, Cell Survival and Differentiation Involved in Tumorigenesis. Cell Death & Disease, 8, e2895. https://doi.org/10.1038/cddis.2017.244 |
| [2] | Ogata, K., Hojo, H., Aimoto, S., Nakai, T., Nakamura, H., Sarai, A., et al. (1992) Solution Structure of a DNA-Binding Unit of Myb: A Helix-Turn-Helix-Related Motif with Conserved Tryptophans Forming a Hydrophobic Core. Proceedings of the National Academy of Sciences, 89, 6428-6432. https://doi.org/10.1073/pnas.89.14.6428 |
| [3] | Lipsick, J.S., Manak, J., Mitiku, N., Chen, C., Fogarty, P. and Guthrie, E. (2001) Functional Evolution of the Myb Oncogene Family. Blood Cells, Molecules, and Diseases, 27, 456-458. https://doi.org/10.1006/bcmd.2001.0404 |
| [4] | Tarasov, K.V., Tarasova, Y.S., et al. (2008) B-MYB Is Essential for Normal Cell Cycle Progression and Chromosomal Stability of Embryonic Stem Cells. https://dash.harvard.edu/handle/1/7628330 |
| [5] | Dyba, T., Randi, G., Bray, F., et al. (2021) The European Cancer Burden in 2020: Incidence and Mortality Estimates for 40 Countries and 25 Major Cancers—PMC. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8568058/ |
| [6] | Jiao, M., Zhang, F., Teng, W. and Zhou, C. (2022) MYBL2 Is a Novel Independent Prognostic Biomarker and Correlated with Immune Infiltrates in Prostate Cancer. International Journal of General Medicine, 15, 3003-3030. https://doi.org/10.2147/ijgm.s351638 |
| [7] | 杨明, 朱旭东, 沈炀, 等. MYBL2在前列腺癌患者组织中高表达并与不良预后相关[J]. 南方医科大学学报, 2022, 42(8): 1109-1118. |
| [8] | Li, Q., Wang, M., Hu, Y., Zhao, E., Li, J., Ren, L., et al. (2021) MYBL2 Disrupts the Hippo-Yap Pathway and Confers Castration Resistance and Metastatic Potential in Prostate Cancer. Theranostics, 11, 5794-5812. https://doi.org/10.7150/thno.56604 |
| [9] | Mu, X., Shen, Z., Lin, Y., Xiao, J., Xia, K., Xu, C., et al. (2022) LncRNA-MALAT1 Regulates Cancer Glucose Metabolism in Prostate Cancer via MYBL2/mTOR Axis. Oxidative Medicine and Cellular Longevity, 2022, 1-15. https://doi.org/10.1155/2022/8693259 |
| [10] | Li, X., Jiao, M., Hu, J., Qi, M., Zhang, J., Zhao, M., et al. (2020) miR-30a Inhibits Androgen-Independent Growth of Prostate Cancer via Targeting MYBL2, FOXD1, and SOX4. The Prostate, 80, 674-686. https://doi.org/10.1002/pros.23979 |
| [11] | Harbeck, N., Penault-Llorca, F., Cortes, J., Gnant, M., Houssami, N., Poortmans, P., et al. (2019) Breast Cancer. Nature Reviews Disease Primers, 5, Article No. 66. https://doi.org/10.1038/s41572-019-0111-2 |
| [12] | Bayley, R., Ward, C. and Garcia, P. (2020) MYBL2 Amplification in Breast Cancer: Molecular Mechanisms and Therapeutic Potential. Biochimica et Biophysica Acta (BBA)—Reviews on Cancer, 1874, Article 188407. https://doi.org/10.1016/j.bbcan.2020.188407 |
| [13] | Li, J. and Chen, H. (2022) Actin-binding Rho Activating C-Terminal Like (ABRACL) Transcriptionally Regulated by MYB Proto-Oncogene Like 2 (MYBL2) Promotes the Proliferation, Invasion, Migration and Epithelial-Mesenchymal Transition of Breast Cancer Cells. Bioengineered, 13, 9019-9031. https://doi.org/10.1080/21655979.2022.2056821 |
| [14] | Reddy, G.M. (2017) Clinicopathological Features of Triple Negative Breast Carcinoma. Journal of Clinical and Diagnostic Research, 11, EC05-EC08. https://doi.org/10.7860/jcdr/2017/21452.9187 |
| [15] | Liu, B., Yao, P., Xiao, F., Guo, J., Wu, L. and Yang, Y. (2021) MYBL2-Induced PITPNA-AS1 Upregulates SIK2 to Exert Oncogenic Function in Triple-Negative Breast Cancer through miR-520d-5p and DDX54. Journal of Translational Medicine, 19, Article No. 333. https://doi.org/10.1186/s12967-021-02956-6 |
| [16] | Siegel, R.L., Miller, K.D., Fuchs, H.E. and Jemal, A. (2021) Cancer Statistics, 2021. CA: A Cancer Journal for Clinicians, 71, 7-33. https://doi.org/10.3322/caac.21654 |
| [17] | Musa, J., Aynaud, M.M., et al. (2017) MYBL2 (B-Myb): A Central Regulator of Cell Proliferation, Cell Survival and Differentiation Involved in Tumorigenesis. Cell Death & Disease, 8, e2895. https://www.nature.com/articles/cddis2017244 |
| [18] | Lee, Y., Wu, Z., Yang, S., Schreiner, S.M., Gonzalez-Smith, L.D. and Rhie, S.K. (2022) Characterizing and Targeting Genes Regulated by Transcription Factor MYBL2 in Lung Adenocarcinoma Cells. Cancers, 14, Article 4979. https://doi.org/10.3390/cancers14204979 |
| [19] | Li, W., Zhang, B., Jia, Y., Shi, H., Wang, H., Guo, Q., et al. (2019) LncRNA LOXL1-AS1 Regulates the Tumorigenesis and Development of Lung Adenocarcinoma through Sponging miR-423-5p and Targeting MYBL2. Cancer Medicine, 9, 689-699. https://doi.org/10.1002/cam4.2641 |
| [20] | Morris, B.B., Wages, N.A., Grant, P.A., Stukenberg, P.T., Gentzler, R.D., Hall, R.D., et al. (2021) MYBL2-Driven Transcriptional Programs Link Replication Stress and Error-Prone DNA Repair with Genomic Instability in Lung Adenocarcinoma. Frontiers in Oncology, 10, Article 585551. https://doi.org/10.3389/fonc.2020.585551 |
| [21] | 中国抗癌协会子宫体肿瘤专业委员会, 中国妇产科精准医学协会, 长三角地区妇科质控委员会, 等. 子宫内膜癌手术治疗质量控制与评价标准中国专家共识(2024年版) [J]. 中国实用妇科与产科杂志, 2024, 40(6): 626-637. https://d.wanfangdata.com.cn/Periodical/zgsyfkyckzz202406014 |
| [22] | Le, L., Luo, J., Wu, F.F., et al. (2021) Overexpression of <em>MYBL2</em> Predicts Poor Prognosis and Promotes Oncogenesis in Endometrial Carcinoma. https://pubmed.ncbi.nlm.nih.gov/33782625/ |
| [23] | Krakstad, C., Tangen, I.L., Hoivik, E.A., Halle, M.K., Berg, A., Werner, H.M., et al. (2015) ATAD2 Overexpression Links to Enrichment of B-Myb-Translational Signatures and Development of Aggressive Endometrial Carcinoma. Oncotarget, 6, 28440-28452. https://doi.org/10.18632/oncotarget.4955 |
| [24] | Torre, L.A., Trabert, B., DeSantis, C.E., Miller, K.D., Samimi, G., Runowicz, C.D., et al. (2018) Ovarian Cancer Statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 284-296. https://doi.org/10.3322/caac.21456 |
| [25] | Shao, W., Lin, Z., Xiahou, Z., Zhao, F., Xu, J., Liu, X., et al. (2024) Single-Cell RNA Sequencing Reveals That MYBL2 in Malignant Epithelial Cells Is Involved in the Development and Progression of Ovarian Cancer. Frontiers in Immunology, 15, Article 1438198. https://doi.org/10.3389/fimmu.2024.1438198 |
| [26] | Pan, B., Wan, T., Zhou, Y., Huang, S., Yuan, L., Jiang, Y., et al. (2023) The MYBL2-CCL2 Axis Promotes Tumor Progression and Resistance to Anti-Pd-1 Therapy in Ovarian Cancer by Inducing Immunosuppressive Macrophages. Cancer Cell International, 23, Article No. 248. https://doi.org/10.1186/s12935-023-03079-2 |
| [27] | Liu, Q., Liu, H., Huang, X., Fan, X., Xiao, Z., Yan, R., et al. (2022) A Targetable MYBL2-ATAD2 Axis Governs Cell Proliferation in Ovarian Cancer. Cancer Gene Therapy, 30, 192-208. https://doi.org/10.1038/s41417-022-00538-2 |
| [28] | Iness, A.N., Felthousen, J., Ananthapadmanabhan, V., Sesay, F., Saini, S., Guiley, K.Z., et al. (2018) The Cell Cycle Regulatory DREAM Complex Is Disrupted by High Expression of Oncogenic B-Myb. Oncogene, 38, 1080-1092. https://doi.org/10.1038/s41388-018-0490-y |
| [29] | Qi, G.H., Zhang, C.Y., et al. (2021) CDCA8, Targeted by MYBL2, Promotes Malignant Progression and Olaparib Insensitivity in Ovarian Cancer. American Journal of Cancer Research, 11, 389-415. https://pubmed.ncbi.nlm.nih.gov/33575078/ |
| [30] | 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版)[J]. 协和医学杂志, 2024, 15(3): 532-559. |
| [31] | Frau, M., Ladu, S., Calvisi, D.F., Simile, M.M., Bonelli, P., Daino, L., et al. (2011) MYBL2 Expression Is under Genetic Control and Contributes to Determine a Hepatocellular Carcinoma Susceptible Phenotype. Journal of Hepatology, 55, 111-119. https://doi.org/10.1016/j.jhep.2010.10.031 |
| [32] | Zhao, J., Wang, W., Liu, T., Zhang, L., Lin, D., Yao, J., et al. (2022) MYBL2 Regulates De Novo Purine Synthesis by Transcriptionally Activating IMPDH1 in Hepatocellular Carcinoma Cells. BMC Cancer, 22, Article No. 1290. https://doi.org/10.1186/s12885-022-10354-4 |
| [33] | Li, Z., Chu, H., Jia, M. and Li, L. (2020) Long Noncoding RNA LINC01139 Promotes the Progression of Hepatocellular Carcinoma by Upregulating MYBL2 via Competitively Binding to miR-30 Family. Biochemical and Biophysical Research Communications, 525, 581-588. https://doi.org/10.1016/j.bbrc.2020.02.116 |
| [34] | Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R.L., Torre, L.A. and Jemal, A. (2018) Global Cancer Statistics 2018: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 68, 394-424. https://doi.org/10.3322/caac.21492 |
| [35] | Long, J., Zhu, B., Tian, T., Ren, L., Tao, Y., Zhu, H., et al. (2023) Activation of UBEC2 by Transcription Factor MYBL2 Affects DNA Damage and Promotes Gastric Cancer Progression and Cisplatin Resistance. Open Medicine, 18, Article 20230757. https://doi.org/10.1515/med-2023-0757 |
| [36] | Deng, Q.X., Wu, L.J., Li, Y.M., et al. (2021) MYBL2 in Synergy with CDC20 Promotes the Proliferation and Inhibits Apoptosis of Gastric Cancer Cells. https://pubmed.ncbi.nlm.nih.gov/34358419/ |
| [37] | He, Q., Ding, Z., Chen, T., Wu, H., Song, J., Xiang, Z., et al. (2023) PFDN2 Promotes Cell Cycle Progression via the hnRNPD-MYBL2 Axis in Gastric Cancer. Frontiers in Oncology, 13, Article 1164070. https://doi.org/10.3389/fonc.2023.1164070 |
